Plandai Biotech Stock Probability of Future Pink Sheet Price Finishing Under 1.87E-4
| PLPL Stock | USD 0.0002 0.0001 100.00% |
Plandai |
Plandai Biotech Target Price Odds to finish below 1.87E-4
The tendency of Plandai Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to drop to $ 0.0002 or more in 90 days |
| 0.0002 | 90 days | 0.0002 | about 61.39 |
Based on a normal probability distribution, the odds of Plandai Biotech to drop to $ 0.0002 or more in 90 days from now is about 61.39 (This Plandai Biotech probability density function shows the probability of Plandai Pink Sheet to fall within a particular range of prices over 90 days) . Probability of Plandai Biotech price to stay between $ 0.0002 and its current price of $2.0E-4 at the end of the 90-day period is about 9.84 .
Given the investment horizon of 90 days Plandai Biotech has a beta of -7.06 indicating as returns on its benchmark rise, returns on holding Plandai Biotech are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, Plandai Biotech is expected to outperform its benchmark. In addition to that Plandai Biotech has an alpha of 10.2347, implying that it can generate a 10.23 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Plandai Biotech Price Density |
| Price |
Predictive Modules for Plandai Biotech
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Plandai Biotech. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Plandai Biotech Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Plandai Biotech is not an exception. The market had few large corrections towards the Plandai Biotech's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Plandai Biotech, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Plandai Biotech within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 10.23 | |
β | Beta against Dow Jones | -7.06 | |
σ | Overall volatility | 0.000048 | |
Ir | Information ratio | 0.19 |
Plandai Biotech Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Plandai Biotech for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Plandai Biotech can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Plandai Biotech is way too risky over 90 days horizon | |
| Plandai Biotech has some characteristics of a very speculative penny stock | |
| Plandai Biotech appears to be risky and price may revert if volatility continues | |
| Plandai Biotech has high likelihood to experience some financial distress in the next 2 years | |
| Plandai Biotech currently holds 50.53 K in liabilities with Debt to Equity (D/E) ratio of 0.95, which is about average as compared to similar companies. Plandai Biotech has a current ratio of 0.01, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Plandai Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, Plandai Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Plandai Biotech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Plandai to invest in growth at high rates of return. When we think about Plandai Biotech's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 411.99 K. Net Loss for the year was (4.01 M) with loss before overhead, payroll, taxes, and interest of (768.91 K). | |
| Plandai Biotech currently holds about 7.96 K in cash with (1.1 M) of positive cash flow from operations. |
Plandai Biotech Technical Analysis
Plandai Biotech's future price can be derived by breaking down and analyzing its technical indicators over time. Plandai Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Plandai Biotech. In general, you should focus on analyzing Plandai Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.
Plandai Biotech Predictive Forecast Models
Plandai Biotech's time-series forecasting models is one of many Plandai Biotech's pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Plandai Biotech's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.
Things to note about Plandai Biotech
Checking the ongoing alerts about Plandai Biotech for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Plandai Biotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Plandai Biotech is way too risky over 90 days horizon | |
| Plandai Biotech has some characteristics of a very speculative penny stock | |
| Plandai Biotech appears to be risky and price may revert if volatility continues | |
| Plandai Biotech has high likelihood to experience some financial distress in the next 2 years | |
| Plandai Biotech currently holds 50.53 K in liabilities with Debt to Equity (D/E) ratio of 0.95, which is about average as compared to similar companies. Plandai Biotech has a current ratio of 0.01, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Plandai Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, Plandai Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Plandai Biotech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Plandai to invest in growth at high rates of return. When we think about Plandai Biotech's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 411.99 K. Net Loss for the year was (4.01 M) with loss before overhead, payroll, taxes, and interest of (768.91 K). | |
| Plandai Biotech currently holds about 7.96 K in cash with (1.1 M) of positive cash flow from operations. |
Other Information on Investing in Plandai Pink Sheet
Plandai Biotech financial ratios help investors to determine whether Plandai Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Plandai with respect to the benefits of owning Plandai Biotech security.